Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Nuvectis Pharma, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 33 | 36 | +3 |
| Shares | 1.28M | 1.51M | +236.0K (+18.5%) |
| Value | $16.5M | $12.6M | −$3.84M (−23.3%) |
New holders (5)
Institutions that held Nuvectis Pharma, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 34,011 | $283.7K | 0.00% |
| Gsa Capital Partners LLP | 27,313 | $228.0K | 0.02% |
| Susquehanna International Group, LLP | 25,670 | $214.1K | 0.00% |
| Two Sigma Investments, LP | 22,771 | $189.9K | 0.00% |
| Edmond de Rothschild Holding S.A. | 19,170 | $159.9K | 0.00% |
Sold out (2)
Institutions that held Nuvectis Pharma, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Moran Wealth Management, LLC | 16,697 | $215.2K |
| Dorsey Wright & Associates | 1,396 | $18.0K |